Drug Profile
Locnartecan - Tarveda Therapeutics
Alternative Names: HDC SN-38; PEN-866; STA-12-8666; STA-8666Latest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator Madrigal Pharmaceuticals
- Developer Tarveda Therapeutics
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Indolizines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 18 May 2021 National Cancer Institute plans a phase I/II trial for Solid tumours (In adults, In adolescents, Combination therapy, Second-line therapy or greater) in USA (IV) (NCT04890093)
- 18 Mar 2021 Phase I/II development is ongoing in Solid tumours in USA (Tarveda Therapeutics pipeline, March 2021)
- 31 Dec 2020 Chemical structure information added